BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 1-Year High at $7.94

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $7.94 and last traded at $7.94, with a volume of 4483 shares changing hands. The stock had previously closed at $7.85.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. JMP Securities boosted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a research report on Tuesday, May 7th. Needham & Company LLC restated a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.67.

BioCryst Pharmaceuticals Price Performance

The stock has a fifty day simple moving average of $6.59 and a two-hundred day simple moving average of $5.73.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.06. The firm had revenue of $92.80 million during the quarter, compared to analysts’ expectations of $85.62 million. The business’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.28) earnings per share. As a group, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, CFO Anthony Doyle bought 36,300 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was purchased at an average cost of $5.57 per share, for a total transaction of $202,191.00. Following the acquisition, the chief financial officer now owns 266,744 shares of the company’s stock, valued at approximately $1,485,764.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Anthony Doyle bought 36,300 shares of the stock in a transaction on Tuesday, May 14th. The shares were purchased at an average price of $5.57 per share, for a total transaction of $202,191.00. Following the acquisition, the chief financial officer now owns 266,744 shares in the company, valued at $1,485,764.08. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Helen M. Thackray purchased 30,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The shares were bought at an average cost of $5.86 per share, with a total value of $175,800.00. Following the transaction, the insider now directly owns 272,139 shares of the company’s stock, valued at approximately $1,594,734.54. The disclosure for this purchase can be found here. Insiders have acquired 103,601 shares of company stock worth $596,338 in the last three months. Corporate insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CWM LLC grew its holdings in shares of BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,772 shares in the last quarter. Quarry LP purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth approximately $54,000. Seven Eight Capital LP acquired a new position in BioCryst Pharmaceuticals in the 1st quarter valued at $57,000. Natixis lifted its stake in shares of BioCryst Pharmaceuticals by 400.6% during the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 9,350 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of BioCryst Pharmaceuticals by 131.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 5,912 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.